Meta AnalysisID 1411
PEG-天冬酰胺酶对比大肠杆菌来源L-天冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效与安全性：一项Meta分析
CRD42021255547
Does PEG-asparaginase or E. coli L-asparaginase improve the treatment of acute lymphoblastic leukemia in children? Is the usage of both of them safe when administering it to children?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1411
- Evidence Id
- 9969
- Core Evidence Id
- 9969
- Source Meta Analysis Id
- 1366
- Herb2 Meta Analysis Id
- HBMA001366
- Crd Id
- CRD42021255547
- Title
- Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis
- Review Question
- Does PEG-asparaginase or E. coli L-asparaginase improve the treatment of acute lymphoblastic leukemia in children? Is the usage of both of them safe when administering it to children?
- Study Type Included
- Prospective, randomized, controlled trials.
- Condition Being Studied
- The Chemotherapy combination treatments used today to treat Acute Lymphoblastic Leukaemia (ALL) have improved significantly the long-term course of the disease with the overall five-year-survival rate exceeding 80%. One of the main reasons that contributed to this development is the intensive, extended and higher dosed administration of Asparaginase. L-Asparaginase (L-ASP) is a fundamental component during the loading dose with regards to achieving remission of the disease and, likewise, during the maintenance dose with the intention of establishing that remission in both children and adults suffering from ALL. The cytotoxic effect of the exogenous administration of asparaginase is caused by the depletion of the reserve of asparagine in the blood. The natural forms of the enzyme, produced by the bacteria Erwinia chrysanthemi and Escherichia coli, are being used for treatment, much like L-asparaginase’s product created from the conjugation of E. Coli. with polyethylene glycol (Peg-asparaginase, PEG-ASP) with prolonged half-life of 5.5 days instead of the 26 hour half-life of the natural forms. The study aimed to conduct a meta-analysis to compare the efficacy and safety of PEG-Asp with E. coli L-Asp in children with ALL
- Participant
- Children from birth to 18 years old of age diagnosed with Acute Lymphoblastic Leukemia.
- Animal
- Human Disease Modelled
- Intervention
- PEG-asparaginase given at any dose or frequency.
- Comparator Control
- E. coli L-Asp was used as the control group
- Main Outcome
- Treatment success in the clinically assessable population, which was defined as complete responses (CR) and overall response rate (ORR)
- Outcome Measure
- Additional Outcome
- Secondary outcomes included adverse events and discontinuation of treatment that was probably related to effects of the study drug, and all-cause mortality.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Asparaginase; Child; Escherichia coli; Humans; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; pegaspargase
- Contact
- Maria Ioannidou [email protected]
- Organisational Affiliation
- Aristotle University Thessaloniki
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Greece
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-05-17
- Registration Date
- 2021-06-18
- Anticipated Start Date
- 2021-05-02
- Anticipated Completion Date
- 2021-09-30
- Title Cn
- PEG-天冬酰胺酶对比大肠杆菌来源L-天冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效与安全性：一项Meta分析
- Title En
- Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis
- Bilingual Status
- complete